Edwards Lifesciences Corporation : Trading opportunity
Entry price | Target | Stop-loss | Potential |
---|
US$143.92 |
US$0 |
US$139.85 |
-100% |
---|
Take advantage of the uptrend.
Fundamentally, the firm’s Surperformance rating underlines the sound finances, the profitability and the consensus’ optimism. Indeed, the latter is strongly buyer (3/4 of analysts) and has set an average target price displaying an upward potential of 18%. Moreover, EPS estimates were upward revised over the past twelve months.
Edwards Lifesciences is in a bullish trend in the medium and long term. In weekly data, moving averages remain well-oriented. A recent decline brought back the securiorty in the USD 142 support area. This threshold, with the support of the rising 20-week MA, could initiate a technical rebound.
Consequently, investors may open a long position at current prices and target a reversal toward the USD 152.7 pivot point (20-day moving average). A stop loss order should be set at USD 139.85.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.